AB248

DRUG2 trials

Sponsors

Amgen, Washington University School of Medicine

Conditions

Extensive Stage Small Cell Lung CancerTriple Negative Breast Cancer

Phase 1

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

RecruitingNCT07037758

AmgenExtensive Stage Small Cell Lung Cancer

Start: 2025-09-16End: 2031-01-18Target: 380Updated: 2026-05-29

Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients

Not yet recruitingNCT07300475

Washington University School of MedicineTriple Negative Breast Cancer

Start: 2026-10-01End: 2035-06-30Target: 30Updated: 2026-09-04